Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RNAi

- PMLiVE

Alexion’s Soliris gets US approval for myasthenia gravis

New neurology indication could contribute $1.2bn to sales, says analysts

- PMLiVE

Alnylam takes off on APOLLO trial results

Provides first late-stage evidence on the biotech's gene-silencing platform

- PMLiVE

Germany will be first EU launch market for new Soliris indication

Alexion 'currently evaluating' additional European launches for its orphan drug

- PMLiVE

NICE broadens access to Alexion’s rare disease drug Strensiq

New deal offers NHS England a discount for the drug

- PMLiVE

NICE blocks second Alexion rare disease drug in a week

Says high cost and “considerable uncertainties” over long-term benefits prohibit routine NHS use

Alexion Pharmaceutiacal names interim CEO and CFO

Former AZ CEO David Brennan and David Anderson join

- PMLiVE

Alnylam pulls lead drug revusiran after deaths in phase III trial

US biotech has yet to determine the cause of the amyloidosis and cardiomyopathy study fatalities

- PMLiVE

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

Will collaborate on five programmes to explore the cause of genetically defined diseases

- PMLiVE

Dicerna appoints chief financial officer

Jack Green to take on the role on a permanent basis

- PMLiVE

NICE wants more data on Alexion’s orphan drug Kanuma

Calls for 'robust evidence' about the costly rare disease treatment's price and benefits

- PMLiVE

Alexion’s rare bone disorder therapy rejected by NICE

Draft guidance rules Strensiq does not have a compelling enough evidence base

- PMLiVE

Bio investors react as Clinton tweet pledges pricing crackdown

Pharma companies come under scrutiny for pricing policies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links